Golimumab ELISA Kit (DF879038)

Datasheet Compartir producto Copiar información

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	DF879038
Descripción	Golimumab ELISA Kit (DF879038) — Quantitative sandwich ELISA for Golimumab. Sample: Plasma, Serum. Range: 62.5 - 4, 000 ng/mL. Sensitivity: 40.1 ng/mL. Highlights ●Sandwich Format — High specificity, reliable quantification. ●High Sensitivity — Optimized for low-abundance target detection. ●Ready-to-Use — Complete kit with pre-coated plates included.
Tipo de muestra	Plasma, Serum
Sensibilidad	51.11 ng/ml
Rango	125-4000 ng/ml
Número de acceso	CAS: 476181-74-5
Aplicaciones	ELISA
Método de detección	Colorimetric
Tipo de ensayo	Quantitative
Recuperación	80-120%
Envío	2-8 ℃
Estabilidad y almacenamiento	When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20℃, the rest reagents should be store at 4℃.
Especificaciones	Golimumab
Nombres alternativos	CNTO 148, 476181-74-5
Fondo	Golimumab (Simponi®) is a human immunoglobulin G1? monoclonal antibody which is specific for pro-inflammatory cytokine, tumor necrosis factor-a (TNFa). In 2009, it was approved by FDA for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in adult patients. Elevated levels of TNF are found in the synovial fluid of rheumatoid arthritis, including juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis patients and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased levels of TNF are also found in psoriasis (Ps) plaques. Golimumab binds to both the soluble and transmembrane bioactive forms of human TNF and prevent TNF from binding to its receptors and finally inhibits biological activity of TNF.
Nota	For Research Use Only.